Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
P/B ratio for Kronos Bio, Inc. (KRON)
P/B ratio as of 2023: 0.45
According to Kronos Bio, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.45. At the end of 2022 the company had a P/B ratio of 0.37.
P/B ratio history for Kronos Bio, Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.45 |
| 2022 | 0.37 |
| 2021 | 2.16 |
| 2020 | 3.47 |
| 2019 | -61.88 |
| 2018 | -105.56 |